Restructuring Costs

9 Months Ended

Sep. 30, 2018

Restructuring and Related Activities [Abstract]

Restructuring Costs

11. Restructuring Costs

In June 2016, the Company halted investment in PNT2258 and closed the related Phase 2 clinical trials to further enrollment. As a result, the Company closed its research facility in Plymouth, Michigan, renegotiated and terminated certain contracts, and implemented staff reductions in the United States and Canada.

The following table summarizes restructuring activities for the three months ended September 30, 2018 and 2017:

	Three Months Ended September 30,
	2018			2017
	(in thousands)
Beginning balance	$	86		$	206
Adjustments to research and development expense		(10	)		(38	)
Cash payments		(5	)		(58	)
Ending balance	$	71		$	110

The following table summarizes restructuring activities for the nine months ended September 30, 2018 and 2017:

	Nine Months Ended September 30,
	2018			2017
	(in thousands)
Beginning balance	$	137		$	763
Adjustments to research and development expense		(10	)		(112	)
Cash payments		(56	)		(541	)
Ending balance	$	71		$	110

The accrual balance is currently expected to be substantially paid by the end of 2018.